These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 570847)

  • 41. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials.
    Macconi D; Benigni A; Morigi M; Ubiali A; Orisio S; Livio M; Perico N; Bertani T; Remuzzi G; Patrono C
    J Lab Clin Med; 1989 May; 113(5):549-60. PubMed ID: 2541212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A dominant role of thromboxane formation in secondary aggregation of platelets.
    Meyers KM; Seachord CL; Holmsen H; Smith JB; Prieur DJ
    Nature; 1979 Nov; 282(5736):331-3. PubMed ID: 503210
    [No Abstract]   [Full Text] [Related]  

  • 44. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity.
    Ushikubi F; Okuma M; Kanaji K; Sugiyama T; Ogorochi T; Narumiya S; Uchino H
    Thromb Haemost; 1987 Apr; 57(2):158-64. PubMed ID: 2955539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2.
    Scavone M; Femia EA; Caroppo V; Cattaneo M
    Eur Heart J; 2016 Nov; 37(44):3347-3356. PubMed ID: 26516174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet aggregation in whole blood: the role of thromboxane A2 and adenosine diphosphate.
    Carter AJ; Heptinstall S
    Thromb Haemost; 1985 Oct; 54(3):612-6. PubMed ID: 3937261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of platelet thromboxane generation by suloctidil in man.
    Bucchi F; Cerletti C; de Gaetano G
    Haemostasis; 1986; 16(5):362-8. PubMed ID: 3023210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.
    Robertson RM; Robertson D; Roberts LJ; Maas RL; FitzGerald GA; Friesinger GC; Oates JA
    N Engl J Med; 1981 Apr; 304(17):998-1003. PubMed ID: 7010173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arachidonic acid-induced platelet aggregation and thromboxane A2 generation in patients with coronary heart disease.
    Szczeklik A; Gryglewski RJ; Musiał J; Grodzínska L; Serwónska M; Wójcik-Switek L; Marcinkiewicz E
    Acta Biol Med Ger; 1978; 37(5-6):741-2. PubMed ID: 742286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and structure of the platelet aggregation factor thromboxane A2.
    Bhagwat SS; Hamann PR; Still WC; Bunting S; Fitzpatrick FA
    Nature; 1985 Jun 6-12; 315(6019):511-3. PubMed ID: 4000279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity.
    Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y
    Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients.
    Mayfield RK; Halushka PV; Wohltmann HJ; Lopes-Virella M; Chambers JK; Loadholt CB; Colwell JA
    Diabetes; 1985 Nov; 34(11):1127-33. PubMed ID: 3930325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Changes in platelet sensitivity to thromboxane A2 in pediatric patients with nephrotic syndrome].
    Watanabe M; Suzuki J; Suzuki H
    Nihon Jinzo Gakkai Shi; 1996 Aug; 38(8):356-63. PubMed ID: 8828355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.